Indian health care workers who were administered Covishield have shown better antibody response than the Covaxin recipients, according to a recent study conducted by Coronavirus Vaccine-induced Antibody Titre (COVAT).
The study was done on 515 health care workers who have received both doses of either of the two COVID vaccines.
Among the 515 health care workers (305 male and 210 female), 95 per cent showed seropositivity after two doses of both vaccines. Of the 425 Covishield recipients, 98.1 per cent showed seropositivity, and of the 90 Covaxin recipients, 80 per cent showed seropositivity.
Seropositivity means having the presence of antibodies in the blood serum.
One dose of Covishield produced 10 times more antibodies than Covaxin, according to the study. After a second dose was added, it was found that two shots of Covishield produced about six times more antibodies than Covaxin.
“This ongoing, Pan-India, Cross-sectional, Coronavirus Vaccine-induced Antibody Titre (COVAT) study is being conducted amongst HCW, with or without past history of SARS-CoV-2 infection. SARS-CoV-2 anti-spike binding antibody is being assessed quantitatively at four time points between 21 days or more after the first dose to 6 months after the second dose,” the study further said.
According to endocrinologist Dr Awadhesh Kumar Singh of G D Hospital & Diabetes Institute, Kolkata, the study was not to comment on which one is a better vaccine, but to look at the real-world effectiveness of vaccination.
Bharat Biotech’s Covaxin and Oxford-Astra Zeneca’s Covishield which s being manufactured by Serum Institute of India (India) was given the approval of emergency use authorisation by DCGI-CDSCO in January 2021.